Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Teva
Citi
Accenture
Baxter
Farmers Insurance
Fuji
Medtronic
Argus Health
Fish and Richardson

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,114,874

« Back to Dashboard

Which drugs does patent 8,114,874 protect, and when does it expire?

Patent 8,114,874 protects ICLUSIG and is included in one NDA.

This patent has fifty-three patent family members in seventeen countries.
Summary for Patent: 8,114,874
Title:Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Abstract: This invention relates to compounds of the general formula: ##STR00001## in which the variable groups are as defined herein, and to their preparation and use. In particular, the compounds include embodiments in which Ring T is an imidazo[1,2-b]pyridazine ring system, Rings A and B are each aryl and L.sup.1 is --C(O)NR.sup.1-- or --NR.sup.1C(O)--. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases.
Inventor(s): Zou; Dong (Concord, MA), Huang; Wei-Sheng (Acton, MA), Thomas; R. Mathew (Waltham, MA), Romero; Jan Antionette C. (Cambridge, MA), Qi; Jiwei (West Roxbury, MA), Wang; Yihan (Newton, MA), Zhu; Xiaotian (Newton, MA), Shakespeare; William C. (Southborough, MA), Sundaramoorthi; Rajeswari (Chennai, IN), Metcalf, III; Chester A. (Needham, MA), Dalgarno; David C. (Brookline, MA), Sawyer; Tomi K. (Southborough, MA)
Assignee: ARIAD Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:11/644,849
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,114,874

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ariad ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Ariad ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-003 Apr 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Ariad ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-002 Dec 14, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,114,874

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,029,533 Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors ➤ Subscribe
8,278,307 Monocyclic Heteroaryl compounds ➤ Subscribe
8,461,167 Acetylenic heteroaryl compounds ➤ Subscribe
9,090,561 Acetylenic heteroaryl compounds ➤ Subscribe
8,778,942 Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors ➤ Subscribe
8,470,851 Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors ➤ Subscribe
9,278,971 Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,114,874

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 103044432 ➤ Subscribe
Canada 2634923 ➤ Subscribe
Canada 2650273 ➤ Subscribe
Canada 2651822 ➤ Subscribe
China 101389338 ➤ Subscribe
China 101489558 ➤ Subscribe
China 101490053 ➤ Subscribe
China 103467385 ➤ Subscribe
China 103435595 ➤ Subscribe
Cyprus 1113907 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Accenture
Covington
Argus Health
Johnson and Johnson
Federal Trade Commission
McKinsey
Novartis
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot